Pediatric Acute Lymphoblastic Leukemia: NCCN 2025 Guidance
Pediatric ALL is a highly treatable childhood leukemia managed with phased chemotherapy, risk adaptation, and strong supportive care.
Overview
Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer, arising from immature white blood cells. It is classified by cell type, including B-cell and T-cell forms.
Diagnosis requires showing at least 20% lymphoblasts in the bone marrow. Genetic features help assign risk and guide therapy.
Treatment Approach
Treatment proceeds in phases: induction, consolidation, and maintenance chemotherapy. BCR::ABL1-positive ALL adds a targeted tyrosine kinase inhibitor to standard therapy.
Care is highly risk-adapted and delivered at specialized centers. Clinical trials remain an important option for eligible children.
Supportive Care
Preventing and treating infection is central to safe therapy. Antifungal and antibacterial measures, vaccinations, and careful monitoring of drug effects protect the child.
Neurocognitive and psychosocial support should follow children during and after treatment because of possible late effects.
Relapsed Disease
Relapsed ALL is treated with alternative regimens and may involve stem cell transplant. Newer options include CAR T-cell therapy and targeted antibodies for selected patients.
